Advances in patient care through increasingly individualized therapy
- 2 January 2019
- journal article
- editorial
- Published by Springer Nature in Nature Reviews Clinical Oncology
- Vol. 16 (2) , 73-74
Abstract
No abstract availableKeywords
This publication has 8 references indexed in Scilit:
- Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemiaBlood, 2019
- Functional genomic landscape of acute myeloid leukaemiaNature, 2018
- CPX-351 (cytarabine and daunorubicin) Liposome for Injection Versus Conventional Cytarabine Plus Daunorubicin in Older Patients With Newly Diagnosed Secondary Acute Myeloid LeukemiaJournal of Clinical Oncology, 2018
- Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trialThe Lancet Oncology, 2018
- Durable Remissions with Ivosidenib in IDH1 -Mutated Relapsed or Refractory AMLNew England Journal of Medicine, 2018
- Phase 1/2 Study of Venetoclax with Low-Dose Cytarabine in Treatment-Naive, Elderly Patients with Acute Myeloid Leukemia Unfit for Intensive Chemotherapy: 1-Year OutcomesBlood, 2017
- Midostaurin plus Chemotherapy for Acute Myeloid Leukemia with aFLT3MutationNew England Journal of Medicine, 2017
- A Phase 2 Randomized Study of Low Dose Ara-C with or without Glasdegib (PF-04449913) in Untreated Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic SyndromeBlood, 2016